{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T21:18:18Z","timestamp":1790111898424,"version":"4.0.1"},"reference-count":28,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2004,1,1]],"date-time":"2004-01-01T00:00:00Z","timestamp":1072915200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["European Journal of Oncology Nursing"],"published-print":{"date-parts":[[2004]]},"DOI":"10.1016\/j.ejon.2004.06.006","type":"journal-article","created":{"date-parts":[[2004,9,3]],"date-time":"2004-09-03T03:54:10Z","timestamp":1094183650000},"page":"S16-S30","source":"Crossref","is-referenced-by-count":30,"special_numbering":"S1","title":["Management of adverse events and other practical considerations in patients receiving capecitabine (Xeloda\u00ae)"],"prefix":"10.1016","volume":"8","author":[{"given":"Hilde","family":"Mars\u00e9","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric","family":"Van Cutsem","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Axel","family":"Grothey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sonia","family":"Valverde","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"2","key":"10.1016\/j.ejon.2004.06.006_bib1","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1200\/JCO.1999.17.2.485","article-title":"Multicenter phase II study of capecitabine in paclitaxel-refractory metastatic breast cancer","volume":"17","author":"Blum","year":"1999","journal-title":"Journal of Clinical Oncology"},{"issue":"7","key":"10.1016\/j.ejon.2004.06.006_bib2","doi-asserted-by":"crossref","first-page":"1759","DOI":"10.1002\/1097-0142(20011001)92:7<1759::AID-CNCR1691>3.0.CO;2-A","article-title":"Multicenter, phase II study of oral capecitabine in taxane-pretreated metastatic breast carcinoma patients","volume":"92","author":"Blum","year":"2001","journal-title":"Cancer"},{"key":"10.1016\/j.ejon.2004.06.006_bib3","first-page":"2755","article-title":"A phase I study of capecitabine in combination with oral leucovorin in patients with intractable solid tumors","volume":"4","author":"Cassidy","year":"1998","journal-title":"Clinical Cancer Research"},{"key":"10.1016\/j.ejon.2004.06.006_bib4","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1093\/annonc\/mdf089","article-title":"First-line oral capecitabine therapy in metastatic colorectal cancer","volume":"13","author":"Cassidy","year":"2002","journal-title":"Annals of Oncology"},{"key":"10.1016\/j.ejon.2004.06.006_bib5","doi-asserted-by":"crossref","unstructured":"Cassidy, J., Scheithauer, W., McKendrick, J., Kr\u00f6ning, H., Nowacki, M.P., Seitz, J.F., Twelves, C., Van Hazel, G., Wong, A., D\u00edaz-Rubio, E., On Behalf Of X-act Study Investigators, 2004. Capecitabine (X) vs bolus 5-FU\/leucovorin (LV) as adjuvant therapy for colon cancer (the X-ACT study): efficacy results of a phase III trial. Proceedings of the American Society of Clinical Oncology (abstract 3509).","DOI":"10.1200\/jco.2004.22.14_suppl.3509"},{"key":"10.1016\/j.ejon.2004.06.006_bib6","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1007\/s002800100366","article-title":"Phase I trial of capecitabine in combination with interferon alpha in patients with metastatic renal cancer","volume":"48","author":"Chang","year":"2001","journal-title":"Cancer Chemotherapy and Pharmacology"},{"issue":"6","key":"10.1016\/j.ejon.2004.06.006_bib7","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1097\/00002820-200312000-00007","article-title":"Palliation of oral mucositis symptoms in pediatric patients treated with cancer chemotherapy","volume":"26","author":"Cheng","year":"2003","journal-title":"Cancer Nursing"},{"key":"10.1016\/j.ejon.2004.06.006_bib8","unstructured":"Chin, S.F., Tchen, N., Oza, A.M., Moore, M.J., Warr, D., Siu, L.L., 2001. Use of \u201cbag balm\u201d as topical treatment of palmar-plantar erythrodysesthesia syndrome in patients receiving selected chemotherapeutic agents. Proceedings of the American Society of Clinical Oncology 20(abstract 1632)."},{"issue":"1","key":"10.1016\/j.ejon.2004.06.006_bib9","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1159\/000180580","article-title":"Prediction of creatinine clearance from serum creatinine","volume":"16","author":"Cockcroft","year":"1976","journal-title":"Nephron"},{"key":"10.1016\/j.ejon.2004.06.006_bib10","unstructured":"Cancer Therapy Evaluation Program, 2003. Common Terminology Criteria for Adverse Events, Version 3.0, DCTD, NCI, NIH, DHHS. March 31, 2003 (http:\/\/ctep.cancer.gov), publication date: December 12, 2003."},{"issue":"1","key":"10.1016\/j.ejon.2004.06.006_bib11","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1046\/j.1365-2125.1998.00050.x","article-title":"Sorivudine and 5-fluorouracil","volume":"46","author":"Diasio","year":"1998","journal-title":"British Journal of Clinical Pharmacology"},{"key":"10.1016\/j.ejon.2004.06.006_bib12","first-page":"921","article-title":"Randomized clinical trial of chlorhexidine versus placebo for prevention of oral mucositis in patients receiving chemotherapy","volume":"23","author":"Dodd","year":"1996","journal-title":"Oncology Nursing Forum"},{"key":"10.1016\/j.ejon.2004.06.006_bib13","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1016\/j.ejca.2003.11.007","article-title":"Multicentre, phase II study evaluating capecitabine monotherapy in patients with anthracycline- and taxane-pretreated metastatic breast cancer","volume":"40","author":"Fumoleau","year":"2004","journal-title":"European Journal of Cancer"},{"issue":"2","key":"10.1016\/j.ejon.2004.06.006_bib14","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1097\/00002820-200304000-00011","article-title":"Current Canadian experience with capecitabine","volume":"26","author":"Gerbrecht","year":"2003","journal-title":"Cancer Nursing"},{"issue":"8","key":"10.1016\/j.ejon.2004.06.006_bib15","doi-asserted-by":"crossref","first-page":"2282","DOI":"10.1200\/JCO.2001.19.8.2282","article-title":"Comparison of oral capecitabine versus intravenous fluorouracil plus leucovorin as first-line treatment in 605 patients with metastatic colorectal cancer","volume":"19","author":"Hoff","year":"2001","journal-title":"Journal of Clinical Oncology"},{"issue":"5","key":"10.1016\/j.ejon.2004.06.006_bib16","doi-asserted-by":"crossref","first-page":"353","DOI":"10.2165\/00002018-200124050-00002","article-title":"Management of chemotherapy-induced adverse effects in the treatment of colorectal cancer","volume":"24","author":"Jansman","year":"2001","journal-title":"Drug Safety"},{"key":"10.1016\/j.ejon.2004.06.006_bib18","unstructured":"MASCC Antiemetic guidelines (2004) at: http:\/\/www.mascc.org."},{"issue":"4","key":"10.1016\/j.ejon.2004.06.006_bib17","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1517\/14622416.3.4.485","article-title":"Implications of dihydropyrimidine dehydrogenase on 5-fluorouracil pharmacogenetics and pharmacogenomics","volume":"3","author":"Mattison","year":"2002","journal-title":"Pharmacogenomics"},{"issue":"2","key":"10.1016\/j.ejon.2004.06.006_bib19","first-page":"791","article-title":"A possible mechanism of eighteen patient deaths caused by interactions of sorivudine, a new antiviral drug, with oral 5-fluorouracil prodrugs","volume":"287","author":"Okuda","year":"1998","journal-title":"Journal of Pharmacology and Experimental Therapeutics"},{"issue":"9","key":"10.1016\/j.ejon.2004.06.006_bib20","doi-asserted-by":"crossref","first-page":"1247","DOI":"10.1023\/A:1012281104865","article-title":"Randomized, open-label, phase II trial of oral capecitabine (Xeloda\u00ae) vs. a reference arm of intravenous CMF (cyclophosphamide, methotrexate and 5-fluorouracil) as first-line therapy for advanced\/metastatic breast cancer","volume":"12","author":"O\u2019Shaughnessy","year":"2001","journal-title":"Annals of Oncology"},{"issue":"12","key":"10.1016\/j.ejon.2004.06.006_bib21","doi-asserted-by":"crossref","first-page":"2812","DOI":"10.1200\/JCO.2002.09.002","article-title":"Superior survival with capecitabine plus docetaxel combination therapy in anthracycline-pretreated patients with advanced breast cancer","volume":"20","author":"O\u2019Shaughnessy","year":"2002","journal-title":"Journal of Clinical Oncology"},{"key":"10.1016\/j.ejon.2004.06.006_bib22","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1007\/s00280-001-0408-0","article-title":"Effect of renal impairment on the pharmacokinetics and tolerability of capecitabine (Xeloda) in cancer patients","volume":"49","author":"Poole","year":"2002","journal-title":"Cancer Chemotherapy and Pharmacology"},{"issue":"8","key":"10.1016\/j.ejon.2004.06.006_bib23","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.1093\/annonc\/mdg346","article-title":"Multicenter phase II study of oral capecitabine (Xeloda) in patients with metastatic breast cancer relapsing after treatment with a taxane-containing therapy","volume":"14","author":"Reichardt","year":"2003","journal-title":"Annals of Oncology"},{"issue":"2","key":"10.1016\/j.ejon.2004.06.006_bib24","doi-asserted-by":"crossref","first-page":"85","DOI":"10.2165\/00003088-200140020-00002","article-title":"Clinical pharmacokinetics of capecitabine","volume":"40","author":"Reigner","year":"2001","journal-title":"Clinical Pharmacokinetics"},{"issue":"12","key":"10.1016\/j.ejon.2004.06.006_bib25","doi-asserted-by":"crossref","first-page":"1735","DOI":"10.1093\/annonc\/mdg500","article-title":"Oral capecitabine as an alternative to i.v. 5-fluorouracil-based adjuvant therapy for colon cancer: safety results of a randomized, phase III trial","volume":"14","author":"Scheithauer","year":"2003","journal-title":"Annals of Oncology"},{"issue":"Suppl. 1","key":"10.1016\/j.ejon.2004.06.006_bib28","doi-asserted-by":"crossref","first-page":"S4","DOI":"10.1016\/j.ejon.2004.06.005","article-title":"Development of and clinical experience with capecitabine (Xeloda\u00ae) in the treatment of solid tumours","volume":"8","author":"Sternberg","year":"2004","journal-title":"European Journal of Oncology Nursing"},{"issue":"9","key":"10.1016\/j.ejon.2004.06.006_bib26","doi-asserted-by":"crossref","first-page":"1367","DOI":"10.1038\/sj.bjc.6600261","article-title":"Randomised, phase II trial comparing oral capecitabine (Xeloda\u00ae) with paclitaxel in patients with metastatic\/advanced breast cancer pretreated with anthracyclines","volume":"86","author":"Talbot","year":"2002","journal-title":"British Journal of Cancer"},{"issue":"21","key":"10.1016\/j.ejon.2004.06.006_bib27","doi-asserted-by":"crossref","first-page":"4097","DOI":"10.1200\/JCO.2001.19.21.4097","article-title":"Oral capecitabine compared with intravenous fluorouracil plus leucovorin in patients with metastatic colorectal cancer","volume":"19","author":"Van Cutsem","year":"2001","journal-title":"Journal of Clinical Oncology"}],"container-title":["European Journal of Oncology Nursing"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1462388904000535?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1462388904000535?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,4,3]],"date-time":"2020-04-03T03:19:48Z","timestamp":1585883988000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1462388904000535"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2004]]},"references-count":28,"alternative-id":["S1462388904000535"],"URL":"https:\/\/doi.org\/10.1016\/j.ejon.2004.06.006","relation":{},"ISSN":["1462-3889"],"issn-type":[{"value":"1462-3889","type":"print"}],"subject":[],"published":{"date-parts":[[2004]]}}}